U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199569) titled 'Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells' on Sept. 22.
Brief Summary: andomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken
embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Study Start Date: Oct. 31
Study Type: INTERVENTIONAL
Condition:
Monkeypox (Mpox)
Intervention:
BIOLOGICAL: Jynneos
MVA-BN manufactured in primary CEF cells. MVA-BN (CEF) vaccine contains 0.5 x 10E8 to 3.95 x 10E8 Inf.U and is an LF suspension to be administered subcutaneously into the d...